dabrafenib and trametinib plus pembrolizumab for braf-mutant melanoma
Published 2 years ago • 207 plays • Length 6:51Download video MP4
Download video MP3
Similar videos
-
2:46
long-term outcomes with dabrafenib plus trametinib in braf v600-mutant melanoma
-
0:53
dabrafenib plus trametinib demonstrates benefit in braf-mutant melanoma
-
0:59
the success of the dabrafenib and trametinib combination in braf-mutated melanoma
-
1:52
dr. long on dabrafenib/trametinib in braf v600e-mutant melanoma
-
4:24
dabrafenib/trametinib/pembrolizumab for advanced melanoma: update from keynote-022
-
2:19
dr. robert on 5-year analysis of dabrafenib/trametinib in braf v600-mutant melanoma
-
0:30
dr. postow on fda approval of adjuvant dabrafenib plus trametinib in braf-mutant melanoma
-
2:56
treating braf v600e-mutant nsclc with dabrafenib and trametinib
-
7:32
continuous vs intermittent dosing of dabrafenib and trametinib in braf mutated melanoma
-
1:31
dr. daud on dabrafenib/trametinib vs immunotherapy in melanoma
-
2:11
dr. georgina long on dabrafenib and trametinib in braf-mutated melanoma
-
2:33
dr. sullivan discusses role of dabrafenib plus trametinib in melanoma
-
6:16
dabrafenib plus trametinib for stage iii mutant melanoma
-
1:49
combi-ad: dabrafenib plus trametinib in advanced melanoma
-
2:51
combi-ad: long-term follow-up of dabrafenib and trametinib in braf-mutated melanoma
-
3:18
dabrafenib plus trametinib for the treatment of mnsclc
-
2:31
neoadjuvant therapy with trametinib and dabrafenib in high risk resectable braf-mutant melanoma
-
1:27
bgb324 with pembrolizumab or dabrafenib/trametinib in melanoma
-
6:28
dabrafenib and trametinib in braf-mutated nsclc